Future Research Will Involve Combination Studies for Merkel Cell Carcinoma

aacr2017 has 92 videos Subscribe Here

Description: Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains the impact of data on future research, stating that avelumab is the only FDA approved drug for Merkel Cell Carcinoma, and with moving forward, future research will involve immunotherapy and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Shared By : aacr2017
Posted on : 04/27/17
Added : 7 months ago


Nothing found.

More From aacr2017

Nothing found.